physiciansweekly.com
Upadacitinib in Crohn’s Disease Real-World Efficacy and Safety
This study provides real‑world data on upadacitinib’s ability to produce clinical and endoscopic remission in people with Crohn’s disease, information that can help patients and clinicians weigh treatment options.
Safety results were consistent with prior trials, which may reassure providers considering this JAK1 inhibitor for patients who have failed other therapies.
Adults with Crohn’s disease considering or currently on advanced therapies, clinicians who treat IBD, and researchers studying real‑world outcomes of JAK inhibitors.
What To Know
What to know This article summarizes a multicentre retrospective study reported in Clinical Gastroenterology and Hepatology that evaluated real‑world effectiveness and safety of upadacitinib (a selective JAK1 inhibitor) for Crohn’s disease.
The study included 334 patients treated with upadacitinib 45 mg induction and reported clinical remission at 12 weeks and endoscopic remission at 6 months, with response rates varying by prior exposure to advanced therapies. Adverse events and discontinuation rates were described and no new safety signals were reported.
Study details and limits The report is a secondary summary of a published multi‑center retrospective analysis rather than a randomized trial. Definitions used included Harvey‑Bradshaw Index for clinical remission and a Simplified Endoscopic Mucosal Assessment for endoscopic remission.
Because this is observational real‑world data, results may be affected by selection bias, varying assessment schedules across centers, and lack of randomized comparators.
Practical takeaway These findings support that upadacitinib can induce clinical and endoscopic remission in a substantial proportion of patients with Crohn’s disease, including those with prior exposure to other advanced therapies, but effectiveness appeared higher in treatment‑naïve patients. Safety in this cohort was consistent with prior trial data.
Decisions about treatment should be individualized and discussed with a clinician.
These results come from a retrospective, multi‑center observational study; they do not replace randomized controlled trials. Differences in prior therapy exposure, BMI, and disease duration were associated with outcomes, suggesting patient selection influences response. Read the original Clinical Gastroenterology and Hepatology article for full methods and detailed results.
